Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory

2026-02-10 05:28:03 ET

Overview

I last covered Anavex Life Sciences ( AVXL ) in November. That was when Anavex was awaiting a decision from EU regulatory authorities regarding its lead drug candidate, blarcamesine, for the treatment of mild Alzheimer's disease ((AD)). I noted that the EU review escalated its application to Day 180, which ordinarily indicates outstanding issues. I thought this lowered the odds of a positive opinion....

Read the full article on Seeking Alpha

For further details see: